News archive

14 November 2023 07:00

Time to raise the beer game: Chr. Hansen unveils two strains for more flavors in non-alcoholic brewing with SmartBev® NEER®

November 14, 2023 – In line with the growing demand for non-alcoholic beer options and flavor variety, Chr. Hansen is committed to providing brewers with top-notch technology to cater to this lucrative market segment and launches two new strains for non-alcoholic brewing.
"With new strains in our portfolio, brewers can now offer an even greater variety of flavors to consumers who are seeking no

8 November 2023 07:07

Canada approves gut-brain axis health claims for Chr. Hansen probiotic strain

Health Canada authorizes functional claims that the probiotic strain DDS-1® “helps alleviate perceived stress and improve irritable bowel syndrome-related quality of life in adolescents and adults”

The ‘gut-brain axis’ has become one of the most cutting-edge areas of research over the past few years, diving into how the fascinating interplay between the brain, gut and microbiome can impact

12 October 2023 06:04

Chr. Hansen reports strong Q4 performance despite a challenging environment

Statement by CEO Mauricio Graber: “Supported by a strong Q4 performance, Chr. Hansen delivered a solid result for the first twelve months of the extended financial year 2022/23 at the upper end of our guidance with 11% organic revenue growth and an EBIT margin b.s.i. of 26.9%. Throughout the year, we have demonstrated the attractiveness of the markets we serve and the resilience of our business mo

27 September 2023 08:02

Chr. Hansen achieves first step Chinese approvals of 3 HMOs

The three HMOs, 2’-FL, LNT and 3-FL, have just been approved by the Chinese Ministry of Agriculture and Rural Affairs, MARA, bringing Chr. Hansen’s HMOs one step closer to final approval for the Chinese market.

18 September 2023 06:56

New Chr. Hansen review of 26 clinical studies reports beneficial effects of HMO in gut health and immune system

Clinical studies in infants, children and adults consistently found that HMO supplementation was safe and well tolerated.

6 July 2023 06:05

Chr. Hansen reports solid results for Q3 with 9% organic growth

Strong execution by the organization drives solid Q3 results
Statement by CEO Mauricio Graber: “The solid results for Q3 prove the strength of the Chr. Hansen organization which continues to deliver first-class products and innovative solutions to customers around the world, while the process with Novozymes to complete the proposed merger is progressing. Organic growth came in at 9%, driven ma

23 June 2023 14:13

Change of Management in Bacthera AG

CEO Lukas Schüpbach has decided to step down from his role at Bacthera, effective August 31st, 2023
Lukas Schüpbach has been with the company since 2020. Lukas has played a critical role in the establishment of Bacthera as a leading global end-to-end contract development and manufacturing service provider in the Live Biotherapeutics industry with clinical and commercial manufacturing sites in S

12 June 2023 06:14

Chr. Hansen secures EU approval for the final HMO in its 5 HMO Mix

The 6’-SL HMO from Chr. Hansen is approved for highest use levels in infant formula and follow-on formula in EU

As of June 4, 2023, Chr. Hansen’s HMO 6’-Sialyllactose sodium salt (6’-SL), marketed under the new trademark MyOli™ 6’-SL HMO, is authorized for the EU market and under proprietary protection for five years. This EU authorization includes the highest use level for 6’-SL in infant

13 April 2023 06:11

Chr. Hansen reports strong results for Q2: 11% organic growth

A strong first half supporting the full-year outlook
Statement by CEO Mauricio Graber: “The strong results for Q2 confirm the attractiveness of the markets we serve in FC&E and H&N, and the resilience of our customer-focused business model. Organic growth came in higher than expected and reached 11%, driven by both pricing initiatives and volume growth. EBIT b.s.i. increased by 8% des

28 February 2023 08:12

Chr. Hansen HMOs get Novel Food approval in EU  

Final EU authorization of LNT, 3-FL and 3’-SL for safe use in infant formula at the highest dosage levels

Following last May’s positive EFSA assessment of Chr. Hansen’s HMOs lacto-N-tetraose (LNT),  3-fucosyllactose (3-FL) and 3’-sialyllactose (3’-SL), these three important Human Milk Oligosaccharides are now approved in EU for safe use in infant formula and several other categories at the

12 January 2023 07:07

Chr. Hansen reports 10% organic growth for first quarter of 2022/23

Solid Q1 supports the outlook for 2022/23
Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased by 17% supported by the organic growth and exchange rates, leading to an EBIT margin b.s.i. of 24.7%. In light of the Q1 performance we maintain our unde

28 November 2022 08:56

CP Kelco and Chr. Hansen join forces to develop breakthrough, ambient, plant-based “vegurts”

Experience it firsthand at Food Ingredients Europe, stand 4C180, in Paris, on December 6-8

Ingredient powerhouses CP Kelco and Chr. Hansen are proud to offer customers a collaboration combining their world-leading expertise and solutions to take consumer-friendly, shelf-stable, plant-based yogurt alternatives (“vegurts”) to the next level.
Consumer demand for healthy and more sustainab